Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

02 Dec 2020

Thomas Powles, MD; Elizabeth R Plimack, MD; Denis Soulières, MD; Tom Waddell, MD; Viktor Stus, MD; Rustem Gafanov, MD
et al.

The Lancet Oncology, October 23 2020